Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173:989–1001. https://doi.org/10.7326/M20-1443.

Article  PubMed  Google Scholar 

Mitchell A, Adams LA, MacQuillan G, Tibballs J, Vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 2008;14:210–3. https://doi.org/10.1002/lt.21417.

Article  PubMed  Google Scholar 

Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006;85:631–2. https://doi.org/10.1007/s00277-006-0147-8.

Article  PubMed  Google Scholar 

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert- Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Riviere S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948–55. https://doi.org/10.1001/jama.2012.250.

Article  CAS  PubMed  Google Scholar 

Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol. 2014;5:91–5. https://doi.org/10.2500/ar.2014.5.0091.

Article  Google Scholar 

Chavan A, Schumann-Binarsch S, Schmuck B, Oltmer F, Geisthoff U, Hoppe F, Wirsching K, Klempnauer J, Manns M, Köhne CH. Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017;92:E641–4. https://doi.org/10.1002/ajh.24878.

Article  CAS  PubMed  Google Scholar 

Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD, Kamath PS, Misra S, Begna KH, Cartin-Ceba R, DuBrock HM, Krowka MJ, O’Brien EK, Pruthi RK, Schroeder DR, Swanson KL. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia–related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93:155–66. https://doi.org/10.1016/j.mayocp.2017.11.013.

Article  CAS  PubMed  Google Scholar 

Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol. 2016;91:E313–4. https://doi.org/10.1002/ajh.24367.

Article  PubMed  Google Scholar 

Rosenberg T, Fialla AD, Kjeldsen J, Kjeldsen AD. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rhinology. 2019;57:242–51. https://doi.org/10.4193/Rhin18.289.

Article  CAS  PubMed  Google Scholar 

Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS ONE. 2017;12:e0188943. https://doi.org/10.1371/journal.pone.0188943.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-bleed study. Haematologica. 2021;106:2161–9. https://doi.org/10.3324/haematol.2020.261859.

Article  CAS  PubMed  Google Scholar 

Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019;285:223–31. https://doi.org/10.1111/joim.12832.

Article  CAS  PubMed  Google Scholar 

Parambil JG, Gossage JR, McCrae KR, Woodard TD, Menon KV, Timmerman KL, Pederson DP, Sprecher DL, Al-Samkari H. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis. 2021. https://doi.org/10.1007/s10456-021-09807-4.

Article  PubMed  PubMed Central  Google Scholar 

Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CC, McWilliams JP, Parambil JG, Vozoris N, Donaldson J, Paul G. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis. 2019;22:145–55. https://doi.org/10.1007/s10456-018-9646-1.

Article  CAS  PubMed  Google Scholar 

Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121:636–8. https://doi.org/10.1002/lary.21415.

Article  CAS  PubMed  Google Scholar 

Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2012;269:531–6. https://doi.org/10.1007/s00405-011-1721-9.

Article  CAS  PubMed  Google Scholar 

Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Breant V, Colombet B, Riviere S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA. 2016;316:934–42. https://doi.org/10.1001/jama.2016.11387.

Article  CAS  PubMed  Google Scholar 

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316:943–51. https://doi.org/10.1001/jama.2016.11724.

Article  CAS  PubMed  Google Scholar 

Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35:1715–2179. https://doi.org/10.1161/01.STR.0000129334.05181.b6.

Article  CAS  PubMed  Google Scholar 

Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother. 2003;47:3630–3. https://doi.org/10.1128/AAC.47.11.3630-3633.2003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke. 2003;34:925–31. https://doi.org/10.1161/01.STR.0000061888.71524.DF.

Article  CAS  PubMed  Google Scholar 

Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D. Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study. J Neurosurg. 1996;85:838–45. https://doi.org/10.3171/jns.1996.85.5.0838.

Article  CAS  PubMed  Google Scholar 

Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke. 2007;38:2563–8. https://doi.org/10.1161/STROKEAHA.106.481515.

Article  CAS  PubMed  Google Scholar 

Arthur H, Geisthoff U, Gossage JR, Hughes CC, Lacombe P, Meek ME, Oh P, Roman BL, Trerotola SO, Velthuis S, Wooderchak-Donahue W. Executive summary of the 11th HHT international scientific conference. Angiogenesis. 2015;18:511–24. https://doi.org/10.1007/s10456-015-9482-5.

Article  PubMed  Google Scholar 

McWilliams JP, Majumdar S, Kim GH, Lee J, Seals K, Tangchaiburana S, Gilbert S, Duckwiler GR. North American study for the treatment of recurrent epistaxis with doxycycline: the NOSTRIL trial. J Thromb Haemost. 2022;20:1115–25. https://doi.org/10.1111/jth.15662.

Article  CAS  PubMed  Google Scholar 

Purkey MR, Seeskin Z, Chandra R. Seasonal variation and predictors of epistaxis. Laryngoscope. 2014;124:2028–33. https://doi.org/10.1002/lary.24679.

Article  PubMed  Google Scholar 

Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope. 2013;123:1092–9. https://doi.org/10.1002/lary.23893.

Article  PubMed  Google Scholar 

Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64:1085–94. https://doi.org/10.1016/j.jclinepi.2010.12.019.

Article  PubMed  Google Scholar 

Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME, Brain Vascular Malformation Consortium HHT Investigator Group. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017;https://doi.org/10.1002/ajh.24832

Grondin MA, Ruivard M, Perreve A, Derumeaux-Burel H, Perthus I, Roblin J, Thiollieres F, Gerbaud L. Prevalence of iron deficiency and health-related quality of life among female students. J Am Coll Nutr. 2008;27:337–41. https://doi.org/10.1080/07315724.2008.10719709.

Article  PubMed  Google Scholar 

Patterson AJ, Brown WJ, Powers JR, Roberts DC. Iron deficiency, general health and fatigue: results from the Australian longitudinal study on women’s health. Qual Life Res. 2000;9:491–7. https://doi.org/10.1023/A:1008978114650.

Article  CAS  PubMed  Google Scholar 

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19:512–26. https://doi.org/10.1016/j.ccr.2011.02.005.

Article  CAS  PubMed  Google Scholar 

Lewis CE, Ferrara N. Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell. 2011;19:431–3. https://doi.org/10.1016/j.ccr.2011.03.016.

Article